Profile image
Story Views

Last Hour:
Last 24 Hours:

Worldwide MRSA Drugs Market 2016 Trend, Analysis and Overview

Thursday, November 10, 2016 3:20
% of readers think this story is Fact. Add your two cents.

(Before It's News)

MRSA is an infection of the skin that occurs mostly in hospitals and healthcare facilities. It is treated with commonly-used antibiotics and usually spreads from person to person by direct skin-to-skin contact. Physicians often find MRSA harder to treat than most other strains of Staphylococcus aureus because it is sometimes resistant to commonly-used antibiotics such as methicillin.

Publisher’s analysts forecast the global MRSA drugs market to grow at a CAGR of 1.34% during the period 2016-2020.

For more information about this report:   

Covered in this report 
The report covers the present scenario and the growth prospects of the global MRSA drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generic drugs used to treat and prevent MRSA infections.

The market is divided into the following segments based on geography: 
- Americas

Publisher’s report, Global MRSA Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. 

Key vendors 
- Allergan
- Merck & Co.
- Pfizer
- Theravance Biopharma


Request Sample Copy at    


Other prominent vendors
- Absynth Biologics
- AmpliPhi Biosciences Corporation
- AstraZeneca
- Basilea Pharmaceutica 
- Baxter International
- Cellceutix
- Cempra Inc.
- CrystalGenomics
- Debiopharm Group
- Galapagos NV
- KYORIN Pharmaceutical 
- Lytix Biopharma
- Melinta Therapeutics
- Nabriva Therapeutics
- NovaDigm Therapeutics 
- Paratek Pharmaceuticals
- R-Pharm
- Savara Pharmaceuticals
- Sealife Pharma
- Sequella Inc. 
- The Medicines Company
- XBiotech

Market driver 
- Special regulatory designations
- For a full, detailed list, view our report 

Market challenge 
- Development of drug-resistant strains
- For a full, detailed list, view our report 

Market trend 
- Strategic alliances and M&A
- For a full, detailed list, view our report 


Inquire for Report at  


Contact Us:

Call: +1-646-491-9876

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Top Global


Top Alternative




Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.